CD80 and neoplasm: These findings are consistent with previously described evidence of: a) infiltration of immune cells, including macrophages, in human ovarian cancer patient-derived xenograft residual tumours in immunocompromised mice treated with an anti-tumour IgE and human PBMCs as effector cells; and b) higher recruitment of monocyte/macrophages into tumours and enhanced expression of CD80+ rat macrophages into syngeneic tumours in an immunocompetent rat model following systemic treatment with rat MOv18 IgE [4,9].